Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): Significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19: 12–19.
Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised, controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–1167.
Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. Ann Rheum Dis. 2010; 69:88–96.
Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: Tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968–2980. http://www.ncbi.nlm.nih.gov/pubmed/18821691
Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): A double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–997.
Kremer JL, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. Arthritis Rheum 2011; 63 (3): 609–621
Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: Results from a retrospective study (REACTION study). Mod Rheumatol. 2011 Apr;21(2):122-33. Abstract www.ncbi.nlm.nih.gov/pubmed/20953815
Hirabayashi Y, Ishii T, Harigae H. Clinical efficacy of Tocilizumab in patients with active rheumatoid arthritis in real clinical practice. Rheumatol Int. 2010;30:1041–1048 Abstract http://www.ncbi.nlm.nih.gov/pubmed/19701637
Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Syuji Takei, Yoshiya Tanaka, Kyoko Ito, Hisashi Yamanaka: Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients Ann Rheum Dis 2011;70:2148-2151
http://ard.bmj.com/content/70/12/2148.fullGerd R Burmester, E Feist, H Kellner, J Braun, C Iking-Konert, A Rubbert-Roth: Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA), Ann Rheum Dis doi:10.1136/ard.2010.139725 Published Online First 27 December 2010
Full TextEULAR 2011 - FRI0365 COMPARISON OF TOCILIZUMAB AS MONOTHERAPY OR WITH ADD-ON DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND AN INADEQUATE RESPONSE TO PREVIOUS TREATMENTS: ACT-SURE RESULTS. J. Sibilia 1,*, W. Graninger 2, A. Östör 3, J. A. Román Ivorra 4, J. Wollenhaupt 5, A. Stancati 6, C. Bernasconi 6, V. Bykerk 7 and ACT-SURE Study Group. Abstract, https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=58163
EULAR 2011- SAT0306: Tocilizumab Treatment in Patients with Rheumatoid Arthritis and Inadequate Response to DMARDs and/or TNF Inhibitors: ACT-SURE Final Results. Vivian P. Bykerk, Jose Álvaro-Gracia, Jose Andres Román Ivorra, Michael T. Nurmohamed, Karel Pavelka, Corrado Bernasconi, Andrea Stancati, Jean Sibilia, Andrew Östör on behalf of ACT-SURE Study Group
EULAR 2011 -OP0020 TOCILIZUMAB (TCZ) PLUS METHOTREXATE (MTX) DOES NOT HAVE SUPERIOR CLINICAL EFFICACY TO TCZ ALONE IN RA PATIENTS WITH INADEQUATE RESPONSE TO MTX: 24-WEEK RESULTS OF THE ACT-RAY STUDY M. Dougados, T. Huizinga, T. Sheeran, P. Tak, P. Conaghan, F. Navarro-Sarabia, A. Hou , C. Bernasconi , K. Kissel
Abstract
https://b-com.mci-group.com/Abstract/Statistics/AbstractStatisticsViewPage.aspx?AbstractID=58181The Stanford Health Assessment Questionnaire: Dimensions and Practical Applications. Bonnie Bruce* and James F Fries Health and Quality of Life Outcomes 2003, 1:20, doi:10.1186/1477-7525-1-20
http://www.hqlo.com/content/1/1/20EULAR 2007 –- OP0117 Smolen J, Beaulieu A, Rubbert-Roth A, et al. Tocilizumab, a novel monoclonal antibody targeting IL-6 signaling, significantly reduces disease activity in patients with rheumatoid arthritis.
The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation
Kimberly Webster, David Cella, and Kathleen Yost
Health Qual Life Outcomes. 2003; 1: 79. Published online 2003 December 16. doi: 10.1186/1477-7525-1-79
www.ncbi.nlm.nih.gov/pmc/articles/PMC317391/Assessment: SF-36, Lebensqualität transparent machen
http://www.thieme.de/SID-7EE10754-D1187434/local_pdf/physioonline_exklusiv/pp507_assessment_sf-36.pdfEULAR 2010 - FRI0205 - TOCILIZUMAB INHIBITS RADIOGRAPHIC PROGRESSION, IMPROVES PHYSICAL FUNCTION, AND GAINS EFFICACY OVER TIME: LITHE 2 YEAR
R. Fleischmann, R. Burgos-Vargas, F. N. Skopouli, Z.-G. G. Li, P. Ambs, E. Vernon, J. Kremer, Abstract
http://www.abstracts2view.com/eular/view.php?nu=EULAR10L_FRI0205&terms=EULAR 2008 – FRI0172 Smolen J, et al. Tocilizumab rapidly and significantly reduces DAS28 in patients with rheumatoid arthritis inadequately responding to DMARDs: Pooled analysis
ACR 2010 - 1819 -LITHE: Tocilizumab (TCZ) Inhibits Radiographic Progression and Improves Physical Function in Rheumatoid Arthritis (RA) Patients (pts) at 3 Years with Maintenance of Clinical Efficacy over Time. Joel M. Kremer, MD, Daniel E. Furst, Ruben Burgos-Vargas, MD, Jean Dudler, MD, Christopher M. Mela, Emma Vernon, Roy M. Fleischmann, MD
Z DE JONG et al.: THE RELIABILITY AND CONSTRUCT VALIDITY OF THE RAQoL] A RHEUMATOID ARTHRITIS!SPECIFIC QUALITY OF LIFE INSTRUMENT. British Journal of Rheumatology 1997; 36: 878-883, http://rheumatology.oxfordjournals.org/content/36/8/878.full.pdf+html
ACR 2011- 2628 - Double-Blind Study of Tocilizumab Plus Methotrexate Vs Tocilizumab Plus Placebo in Patients with Active Rheumatoid Arthritis Despite Prior Methotrexate: Progression of Structural Damage, Quality of Life, and Physical Function At 24 Weeks. Maxime Dougados et al. Abstract http://acr.confex.com/acr/2011/webprogram/Paper21182.html
Prof. Dr. K. Krüger: „Medizin nach Maß mit RoACTEMRA®“.Roche und Chugai in der Rheumatologie: Highlights vom ACR 2011: Medizin nach Maß mit RoACTEMRA® Frankfurt, Dienstag, 22. November 2011, Roche Pharma AG & Chugai Pharma Marketing Ltd.
Pressemitteilung 08. Juni 2011: Tocilizumab Mono erzielt hohe Remissionsraten. EULAR zeigt erstmals: Monotherapie vergleichbar wirksam wie eine Kombination mit MTX.
RoActemra® Studien bei „Roche in Deutschland“
Fachinformation RoACTEMRA® Stand Juli 2011